Company / SG&A Expense
GYRE THERAPEUTICS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$20.8M
FY2025
5-year range
$16.1M / $20.8M
FY2021-FY2025
Trend
+29.1%
vs FY2024
Sector context
#200 of 213
Health Care
What the data says
Among 213 Health Care companies, GYRE THERAPEUTICS, INC. is in the top 6% for sg&a expense. Increased from $17M to $21M over the past 2 years.
Based on SEC 10-K filings.
$21M in FY2025 with a 5-year CAGR of +9.2%.
Increased from $17M to $21M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +6.2%
- 5-Year CAGR
- +9.2%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 213This company $20.8M Sector average $722.3M
▼
-97.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 29.1% year-over-year.
- Ranks #200 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.8M | +29.1% |
| FY2024 | $16.1M | -7.3% |
| FY2023 | $17.4M | +0.0% |
| FY2022 | $17.4M | -8.4% |
| FY2021 | $19.0M | +41.3% |
| FY2020 | $13.4M | +0.0% |
| FY2019 | $13.4M | +34.3% |
| FY2018 | $10.0M | +0.0% |
| FY2017 | $10.0M | +7.9% |
| FY2016 | $9.3M | -3.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026